Chemical Computing Group

Chemical Computing Group develops and supplies industry-leading computational chemistry and bioinformatics software—primarily MOE—for pharmaceutical, biotechnology, and academic researchers. Their products enable structure-based design, fragment-based design, pharmacophore discovery, protein/antibody modeling, cheminformatics/QSAR analysis, molecular simulations and more. The company’s technologies support the entire drug discovery pipeline from early-stage target identification to lead optimization[1][2][3].

No clinical results as CCG does not conduct clinical trials.

Their user base includes most major pharma/biotech companies globally as well as hundreds of academic institutions[3].

PSILO provides an enterprise-level protein structure database system for managing macromolecular structural data[1].

The company has received recognition through awards such as the ACS COMP CCG Excellence Awards in computational chemistry education/research[3].

No direct pipeline or programs.

Headquarters in Montreal since founding in 1994.

Privately held with ~30+ employees.

[No revenue or funding details publicly available.]

[No evidence of acquisition.]

[Key person Paul Labute – President & CEO.]

[Main website chemcomp.com.]